QRQuinn Rainer

Quinn Rainer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Quinn Rainer has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnosis of infectious disease pathology on whole slide images: a multi‐platform evaluation with implications for digital laboratory practice

    by Nandan Padmanabha, Quinn Rainer, Kanchan Kantekure, Paul A. VanderLaan, Yue Sun, Hemant Varma, Vikram Deshpande, Yuho Ono, Yaileen D. Guzman‐Arocho, Rahul M. Jawale, et al.

    Purpose: Adoption of whole slide imaging (WSI) is accelerating across anatomic pathology practices, yet there is a lack of evidence guiding its use for infectious disease diagnoses. WSI systems usually operate at a maximum of 40X magnification without z‐plane depth, appropriately raising concerns about detecting microorganisms. Methods: We assembled a 15‐case panel (with immunohistochemistry [IHC]/special stains where indicated) spanning bacterial, viral, parasitic and fungal infections of various organ systems, including five organism‐negative ‘controls’. An infectious disease pathologist independently reviewed all glass slides to confirm the diagnoses. Eight board‐certified pathologists reviewed cases (blinded to diagnoses) scanned on one of four high‐throughput scanner platforms (Philips SG300, Hamamatsu S360, Pramana (Spectral HT2) and Leica GT450 designated A‐D (not in order), two pathologists/platform). As a control group, two additional pathologists reviewed the same cases on glass slides. Additionally, in an attempt to compare image quality among the four WSI platforms, 10 pathologists (blinded to the platform) rated image quality from side‐by‐side screenshots in 12 representative cases. Results: Aggregate diagnostic scores were: Scanner A: 78%, Scanner D: 71%, Scanner C: 69% and Scanner B: 65%, (mean 71%) vs. 79% for glass‐slide reviewers. Intra‐platform variability between the two pathologists on the same scanner (up to 23% on platform D) exceeded inter‐platform differences. WSI reviewers performed near‐equivalently to glass‐slide reviewers for large organisms (92% vs. 89%) but lower for small/low‐burden organisms (36% vs. 63%). Conclusions: Diagnostic performance on WSI for infectious disease pathology in this exploratory study varied primarily with organism size and burden, not by platform‐specific image quality differences. WSI is non‐inferior to glass for large organisms, but glass slide review may be superior for small (and low burden) organisms.

  • Open Access

    Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation

    by Quinn Rainer, Yue Sun, Monika Vyas, Pavel Kopach, Dibson Gondim, Vidarshi Muthukumarana, Harshwardhan Thaker, Vikram Deshpande

    Artificial intelligence (AI) has emerged as a promising adjunct in surgical pathology, particularly in the diagnosis of prostate cancer, where variability in interpretation or missed cancer foci can significantly affect patient management. This review provides a concise, practice-oriented overview of the two Food and Drug Administration (FDA)-cleared AI tools for prostate biopsy interpretation: Paige Prostate Detect and Ibex Prostate Detect (formerly Galen Second Read). We examine their regulatory indications, diagnostic performance and integration requirements within digital pathology workflows. Emphasis is placed on real-world implementation considerations, including variation in technical inputs and the level at which data are analysed. We highlight less obvious risks, such as domain shift and the potential for inequitable performance in under-represented patient populations. Trade-offs between sensitivity and specificity, particularly in the context of AI-assisted pathologist assessments, are discussed using data from clinical validation studies. We also consider the variable impact of AI tools depending on the user’s expertise, noting enhanced diagnostic consistency for general pathologists. By highlighting both the opportunities and limitations of integrating AI into routine practice, we aim to provide pathologists with a pragmatic understanding of how these systems may influence diagnostic workflows and to emphasise that FDA clearance must be complemented by local validation as well as ongoing performance monitoring to ensure safe and equitable deployment.

  • Diagnostic yield and cost of three-level H&E sectioning in prostate biopsies

    by Ruth Gichinga, Marcos Lepe, Quinn Rainer, Laura C Collins, Yue Sun

    Aim: The traditional three-level H&E sectioning protocol for prostate biopsies was developed for ultrasound-guided systematic sampling and predates lesion-targeted biopsy approaches. Multiparametrical MRI (mpMRI) has improved detection of clinically significant prostate carcinoma but has also increased biopsy volume, workload, costs and digital pathology requirements, including whole-slide imaging and artificial intelligence (AI) integration. Methods and results: A retrospective institutional cost-yield analysis was performed on prostate biopsy cases at Beth Israel Deaconess Medical Center (2015–2022), comparing systematic 12-core biopsies with combined systematic and mpMRI-targeted biopsies. Case volume, tissue blocks and H&E slides were analysed. Per-slide costs were calculated, and additional digital pathology and AI workflow costs were estimated using published data and vendor pricing. Case volume increased by 27% over 7 years, while combined systematic and mpMRI-targeted protocols increased tissue blocks and H&E slides by 39%. The cost per H&E slide was $7.18, with digital pathology and AI workflows adding an estimated $4.30–5.00 per slide. In systematic 12-core biopsies, third-level sectioning identified four additional low-volume carcinomas at a cost of $2283 per diagnosis. In combined biopsies, two additional carcinomas were detected exclusively on the third level, both Grade Group 1, with a cost of $27 657 per diagnosis. Conclusion: Routine three-level H&E sectioning in combined systematic and mpMRI-targeted prostate biopsies demonstrated low incremental diagnostic yield and substantial additional processing cost. A two-level protocol with selective third-level sectioning may preserve detection of clinically significant carcinomas in this institutional cohort, while reducing workload and cost in the digital pathology era.

  • Pigmented Renal Epithelioid Angiomyolipoma: A Case Report and Literature Review

    by Quinn Rainer, Li Lei, Yue Sun

    Melanin pigmentation in epithelioid angiomyolipoma (AML), a potentially malignant and locally aggressive renal tumor, is an exceptionally rare finding. Accurate differentiation from other pigmented tumors, such as melanoma, pigmented paraganglioma, and pigmented renal cell carcinoma is essential for proper diagnosis and treatment. A retrospective review of 2 departmental archives (2000-2023) identified 2 pigmented renal epithelioid AML specimens. Clinical presentations, histopathological features, immunohistochemical profiles, and molecular findings were analyzed. Both specimens exhibited melanin pigmentation, and 1 tumor demonstrated unique molecular alterations, including TSC2 and TP53 mutations. This study underscores the importance of meticulous histopathological evaluation and molecular profiling in diagnosing and managing this extremely rare variant of epithelioid AML.


  • Transperineal 3T MRI-guided and transrectal MRI-ultrasound fusion prostate biopsies: Do lesion location and size impact diagnostic yield?

    by Quinn Rainer, Kemal Tuncali, Alexander Cole, Quoc-Dien Trinh, Kristine S. Burk, Mark Vangel, Pedro Moreira, Nobuhiko Hata, Clare Tempany

  • Feasibility of MRI‐Guided Transperineal Implantation of Microdevices for Drug Delivery and Response Assessment in Prostate Cancer

    by Quinn Rainer, Kemal Tuncali, Wooseok Ahn, Fanni Viktoria Santa, Michelle Hirsch, Sharath Bhagavatula, Fumitaro Masaki, Clarissa Therese Young, Courtney Marlin, Samantha Martin, et al.

    Background: Prostate cancer (PCa) treatment often involves systemic therapies with varying mechanisms of action, affecting individuals differently. Implantable microdevices (IMDs) are designed to test multiple drugs within a patient's tumor, but the feasibility of MRI‐guided placement in PCa has not been evaluated.Purpose: To provide proof of concept for placing IMDs into lesions with MRI guidance to predict patient‐specific responses to therapies.Study Type: Prospective.Population: Fifteen participants undergoing prostatectomy for PCa.Field Strength/Sequence: 3T MRI With T2‐weighted (T2W).Assessment: In‐bore MRI‐targeted placement of IMDs was performed. Intra‐procedural MRI scans were reviewed by a radiologist, using needle artifacts on T2W images to guide IMD placement. A genitourinary pathologist performed Gleason scoring around the IMDs. Drug response analysis included Enzalutamide + Nivolumab, Enzalutamide + Docetaxel, and single‐agent Enzalutamide.Statistical Tests: Mann–Whitney U test for continuous variables, p < 0.05 for significance.Results: Of 53 IMDs implanted into suspicious lesions in 14 participants, 48 (90%) were successfully placed within the lesions. The average distance from the needle tip to the tumor was 8.32 ± 4.02 mm. Larger lesion size (p = 0.009) and lower prostate imaging‐reporting and data system score (p = 0.031) were significantly associated with successful IMD placement. Of the 53 IMDs, 49 (92.4%) were retrieved for histopathology and drug response analysis. In four participants, Gleason scores around the device were lower than preplacement biopsy in two and equal in two. Additionally, drug analysis in one patient demonstrated the feasibility of drug response analysis, revealing differences in apoptotic index, lymphocyte infiltration, dysplastic cell composition, and cellular profiles for each treatment. No complications or adverse events occurred.Conclusion: IMDs can be effectively and safely placed in prostate lesions using MRI guidance, with feasible histological and drug response analyses. Evidence Level: 2. Technical Efficacy: Stage 1.


  • Open Access

    Pharmacological Screening of Kv7.1 and Kv7.1/KCNE1 Activators as Potential Antiarrhythmic Drugs in the Zebrafish Heart

    by Alicia De la Cruz, Xiaoan Wu, Quinn C. Rainer, Irene Hiniesto-Iñigo, Marta E. Perez, Isak Edler, Sara I. Liin, H. Peter Larsson

    Long QT syndrome (LQTS) can lead to ventricular arrhythmia and sudden cardiac death. The most common congenital cause of LQTS is mutations in the channel subunits generating the cardiac potassium current IKs. Zebrafish (Danio rerio) have been proposed as a powerful system to model human cardiac diseases due to the similar electrical properties of the zebrafish heart and the human heart. We used high-resolution all-optical electrophysiology on ex vivo zebrafish hearts to assess the effects of IKs analogues on the cardiac action potential. We found that chromanol 293B (an IKs inhibitor) prolonged the action potential duration (APD) in the presence of E4031 (an IKr inhibitor applied to drug-induced LQT2), and to a lesser extent, in the absence of E4031. Moreover, we showed that PUFA analogues slightly shortened the APD of the zebrafish heart. However, PUFA analogues failed to reverse the APD prolongation in drug-induced LQT2. However, a more potent IKs activator, ML-277, partially reversed the APD prolongation in drug-induced LQT2 zebrafish hearts. Our results suggest that IKs plays a limited role in ventricular repolarizations in the zebrafish heart under resting conditions, although it plays a more important role when the IKr is compromised, as if the IKs in zebrafish serves as a repolarization reserve as in human hearts. This study shows that potent IKs activators can restore the action potential duration in drug-induced LQT2 in the zebrafish heart.


  • Open Access

    Pharmacological Screening of Kv7.1 and Kv7.1/KCNE1 Activators as Potential Antiarrhythmic Drugs in Zebrafish Heart

    by Alicia De la Cruz, Xiaoan Wu, Quinn Carroll Rainer, Irene Hiniesto-Iñigo, Marta Elena Perez, Isak Edler, Sara Inga Liin, Hans Peter Larsson

    Background: Long QT syndrome (LQTS) can lead to ventricular arrhythmia and sudden cardiac death. The most common congenital cause of LQTS is mutations in the channel subunits generating the cardiac potassium current IKs. Zebrafish (Danio rerio) have been proposed as a powerful system to model human cardiac diseases due to the similar electrical properties of the zebrafish heart and the human heart. Methods: We used high resolution all-optical electrophysiology on ex-vivo zebrafish hearts to assess the effects of IKs analogues on the cardiac action potential. Findings: We found that chromanol 293B (an IKs inhibitor) prolonged the action potential duration (APD) in the presence of E4031 (an IKr inhibitor applied to drug-induced LQT2) and to a lesser extent in the absence of E4031. Moreover, we show that PUFA analogues slightly shorten the APD of the zebrafish heart. However, PUFA analogues failed to reverse the APD prolongation in drug-induced LQT2. However, a more potent IKs activator, ML-277, partially reversed the APD prolongation in drug-induced LQT2 zebrafish hearts. Interpretation: Our results suggest that IKs plays a limited role in ventricular repolarizations in the zebrafish heart under resting conditions but plays a more important role when IKr is compromised, as if IKs in zebrafish serves as a repolarization reserve as in human hearts. This study shows that potent IKs activators can restore the action potential duration in drug-induced LQT2 in zebrafish heart.


  • Sexual Dysfunction Among Adolescent and Young Adult Men Diagnosed with Cancer

    by Quinn Carroll Rainer, Justin Michael Dubin, Navin Chakravarthy Balaji, Victoria Troesch, William Terry, Varun Monga, Lindsey Clifford, Jamie Shoag, Aubrey Greer, Sirpi Nackeeran, et al.

    Purpose: Adolescent and young adult (AYA) cancer patients frequently demonstrate sexual dysfunction; however, there is a lack of data quantifying the severity and frequency. Methods: Males aged 18–39 years, diagnosed with cancer of any kind and who were scheduled to begin, were actively receiving, or had completed cancer treatment within 6 months, were offered validated surveys during their oncology appointment. These surveys included the International Index of Erectile Function (IIEF-6), Masturbation Erection Index (MEI), 36-Item Short Form Survey, and 5-point Likert scales to assess their desire and ability to engage in sex and masturbation. Results: Forty subjects completed the IIEF survey with a mean score of 17.7 ± 11, erectile dysfunction (ED) prevalence accordingly was 58%. Thirty-eight subjects completed the MEI with a mean score of 25.3 ± 5.3, ED prevalence was again 58%. Age and IIEF scores demonstrated a statistically significant ( p < 0.05, n = 38) Pearson's correlation coefficient of 0.40, patients younger than 30 years had an ED prevalence of 72% (mean IIEF 13), whereas patients aged 30 years and older had an ED prevalence of 45% (mean IIEF 22). All treatment modalities had ED rates >30%: chemotherapy demonstrated the highest prevalence at 64% (mean IIEF 17), whereas radiation therapy had the lowest prevalence at 33% (mean IIEF 23). Conclusion: This study demonstrates that the prevalence of sexual dysfunction among male AYA patients undergoing treatment for cancer is high. AYA oncologists should discuss potential sexual health concerns when treating this population. The exact cause of ED (non-organic vs. organic) within this group should be explored further.


  • Open Access

    The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use

    by Quinn Rainer, Raghav Pai, Isaac Zucker, Ranjith Ramasamy, Thomas A Masterson

    Human chorionic gonadotropin (hCG) is homologous to luteinizing hormone (LH) and stimulates endogenous testosterone (T) production. Current American Urological Association (AUA) guidelines recommend hCG for T-deficient men who wish to preserve their fertility. However, there is no data available regarding the long-term efficacy and safety of hCG monotherapy in men with a history of exogenous T use. We hypothesized that transitioning to hCG would be a safe and effective option in this population. We performed a retrospective analysis involving 28 men with previous exogenous T use who were switched to hCG monotherapy and underwent follow-up lab work at least one month later. We evaluated changes in hormones [T, LH, follicle-stimulating hormone (FSH), and estradiol], hematocrit (HCT), glycated hemoglobin (HbA1c), and prostate-specific antigen (PSA). Among the entire cohort, we found no significant change in mean hormone levels (including T), HbA1c, or PSA. There was a significant (p<0.05) decrease in HCT (45.27 ±4.06 to 44.16 ±3.48%, n=15). No thromboembolic events were reported. Additionally, among men who had their baseline labs completed outside their previous T therapy therapeutic time window prior to starting hCG monotherapy, there was a statistically significant increase in mean T levels (307.36 ±148.74 to 422.11 ±268.15 ng/dL, n=30 and 31, pre- and post-hCG, respectively) and a statistically significant decrease in mean PSA levels (0.91 ±0.35 to 0.69 ±0.23 ng/mL, n=5). These results suggest that hCG is a safe and effective alternative to traditional T therapy for men with a history of exogenous T use and may lead to an advantageous decrease in HCT. hCG may serve as an alternative form of T therapy with a lower risk for secondary erythrocytosis, and further research is warranted to gain deeper insights into the topic.